DURHAM, N.C.--(BUSINESS WIRE)--Nov. 7, 2018--
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye, today announced
that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer,
will present in a fireside discussion at the Stifel 2018 Healthcare
Conference on Tuesday, November 13, 2018 at 10:15 a.m. Eastern Time in
New York, NY. Dr. Anido will provide an Aerie overview and business
The fireside discussion will be webcast live and may be accessed by
visiting Aerie's website at http://investors.aeriepharma.com/.
A replay of the webcast will be available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the discovery,
development and commercialization of first-in-class therapies for the
treatment of patients with open-angle glaucoma, retina diseases and
other diseases of the eye. Aerie's first product, Rhopressa®
(netarsudil ophthalmic solution) 0.02%, a once-daily eyedrop approved by
the U.S. Food and Drug Administration (FDA) for the reduction of
elevated intraocular pressure (IOP) in patients with open-angle glaucoma
or ocular hypertension, was launched in the United States in April 2018.
In clinical trials of Rhopressa®, the most common adverse
reactions were conjunctival hyperemia, cornea verticillata, instillation
site pain, and conjunctival hemorrhage. More information about Rhopressa®,
including the product label, is available at www.rhopressa.com.
Aerie’s advanced-stage product candidate, Rocklatan™
(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a fixed-dose
combination of Rhopressa® and the widely-prescribed PGA
(prostaglandin analog) latanoprost, achieved its 3-month primary
efficacy endpoint in two Phase 3 registration trials, Mercury 1 and
Mercury 2, and also showed safety and efficacy throughout 12 months in
Mercury 1. Aerie submitted the Rocklatan™ New Drug Application (NDA) in
May 2018 and, in July 2018, the FDA set the PDUFA (Prescription Drug
User Fee Act) goal date for the completion of the FDA’s review of the
Rocklatan™ NDA for March 14, 2019. Aerie continues to focus on global
expansion and the development of additional product candidates and
technologies in ophthalmology, including for wet age-related macular
degeneration and diabetic macular edema. More information is available
View source version on businesswire.com: https://www.businesswire.com/news/home/20181107005066/en/
Source: Aerie Pharmaceuticals, Inc.
McClellan, Inc., on behalf of Aerie Pharmaceuticals